UK Meta-Analysis Ranks Best Weight-Loss Drugs for Diabetics

A study from the UK, conducted by researchers at Guy's & St. Thomas' Hospital NHS Trust in London, has delivered one of the most comprehensive head-to-head comparisons of obesity medications ever assembled — and the results carry direct implications for the millions of Americans living with obesity-related type 2 diabetes.

What the Researchers Did

Published in Nature Medicine in 2025, this systematic review and network meta-analysis combed through clinical trial data up to January 2025, identifying 56 randomized controlled trials enrolling 60,307 patients. The six medications evaluated were orlistat, semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), tirzepatide (Mounjaro/Zepbound), naltrexone/bupropion (Contrave), and phentermine/topiramate (Qsymia). Researchers measured total body weight loss, blood sugar control, cardiovascular outcomes, and quality of life across follow-up periods of one, two, and three or more years.

Key Findings

Every medication outperformed placebo for weight loss — but not equally. Tirzepatide and semaglutide stood apart, each achieving more than 10% total body weight loss. To put that in practical terms, a 250-pound American patient could expect to lose 25 or more pounds on either medication.

Beyond weight, both tirzepatide and semaglutide demonstrated something remarkable: restoration of normal blood sugar levels and remission of type 2 diabetes in a meaningful portion of patients. Both drugs also reduced hospitalizations due to heart failure.

The benefits diverged in important ways:

• Semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) and relieved pain from knee osteoarthritis.
• Tirzepatide showed effectiveness in reversing obstructive sleep apnea and metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition increasingly common in people with obesity and diabetes.

Understanding the Numbers in US Terms

The study tracked fasting plasma glucose as a key marker. Normal fasting blood sugar in US measurements is under 100 mg/dL (5.6 mmol/L). Prediabetes ranges from 100–125 mg/dL (5.6–6.9 mmol/L), and type 2 diabetes is diagnosed at 126 mg/dL or higher (7.0 mmol/L). The "normoglycemia restoration" reported in this study means patients moved from diabetic or prediabetic ranges back into the healthy zone — a clinically significant achievement that current American Diabetes Association (ADA) guidelines recognize as a treatment goal but one rarely achieved with older medications.

Why This Matters for US Patients

The United States is currently navigating enormous demand for GLP-1 medications like semaglutide and tirzepatide, with ongoing insurance coverage battles and supply challenges. This UK meta-analysis — drawing on 60,000+ patients across international trials — provides the strongest evidence yet that these medications do more than help patients lose weight. They address the cascading complications of obesity: heart disease, diabetes, liver disease, sleep apnea, and joint pain.

For US patients, the study's key takeaway aligns with a growing shift in American clinical thinking: obesity medications should be chosen based on a patient's specific complications, not just their weight. A patient whose primary concern is cardiovascular risk may benefit most from semaglutide, while a patient struggling with sleep apnea or liver disease may be better served by tirzepatide. The researchers explicitly recommend individualized selection of obesity medications — a message that US patients should bring directly to their endocrinologist or primary care provider.

Study Citation

McGowan, Ciudin, & Baker. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Medicine, 2025. DOI: 10.1038/s41591-025-03978-z | PMID: 41039116